Drug Trial Radar · NCT06704009
NT-101 Topical Ophthalmic Solution in Patients With Wet AMD
Last checked: Nov 19, 2026Latest source record: May 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
Mar 11, 2025
Primary completion
Dec 15, 2025
Study completion May 6, 2026
Sponsor
- Lead sponsor
- NexThera Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- KCRN Research, LLC
- First posted
- Nov 25, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 1/2 Trial NT-101 Topical Ophthalmic Solution in Patients with Wet Age-Related Macular Degeneration (AMD)
Conditions
- Wet Age Related Macular Degeneration
- Wet AMD
Interventions
NT-101 Low DoseDrug
Low concentration of NT-101 (0.05 mM)
NT-101 High DoseDrug
High concentration of NT-101 (0.2 mM)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number and Severity of Treatment-Emergent Adverse Events (TEAEs) up to Week 8Time frame: 8 weeks
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Elman Retina Group
Rosedale, Maryland
Duke Eye Center
Durham, North Carolina
Erie Retina Research
Erie, Pennsylvania
Texas Retina Associates
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.